ENTX - Company ID 0001638097
Entera Bio Ltd. trades as ENTX. In its fiscal 2025 annual report the company posted revenue of $42.00K, down 76.8% from the prior year and net income of -$11.44M. This page tracks Entera Bio Ltd. through 382 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 5 fiscal years Entera Bio Ltd.'s revenue declined from $365.00K to $42.00K, a compound annual decline rate of 35.1%. Net profit margin compressed from -3072.9% to -27235.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| EFFECT | - | 2026-05-15 |
| 424B3 | - | 2026-05-15 |
| PRE 14A | - | 2026-05-14 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Securities registration | S-3 | 2026-05-08 |
| Quarterly report | 10-Q | 2026-05-08 |
The largest companies sharing Entera Bio Ltd.'s SEC industry classification (biological products, (no diagnostic substances)).
Entera Bio Ltd. reported revenue of $42.00K for fiscal year 2025, a decrease of 76.8% year over year.
In its latest fiscal year Entera Bio Ltd. reported a net loss of $11.44M.